Effects of Saccharomyces Boulardii capsules in pediatric Inflammatory bowel disease

Evaluation of the effects of lyophilized Saccharomyces Boulardii capsules on quality of life and clinical outcomes in children with inflammatory bowel disease (IBD)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120415009475N5

Enrollment

Registered

2018-10-10

Start date

2018-03-06

Completion date

Unknown

Last updated

2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease.

Interventions

Intervention 1: Intervention group: The patients receive two capsules for two months that each capsule contain 250 milligram Saccharomyces Boulardii. Intervention 2: Control group: this group receive

Eligibility

Sex/Gender

All

Age

1 Years to 16 Years

Inclusion criteria

Inclusion criteria: Children the age of 1-16 Children with IBD

Exclusion criteria

Exclusion criteria: primary and secondary immunodeficiency allergy to drug

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: In this study we checked the effects of Saccharomyces Boulardii capsules in the beginning of the study and two months later. Method of measurement: by interview and completing Visual Analogue Scale by patients.;Quality of life. Timepoint: In this study we checked the effects of Saccharomyces Boulardii capsules in the beginning of the study and two months later. Method of measurement: By interview and completing IMPACT III questionnaire.	—

Measure

Time frame

Pain. Timepoint: In this study we checked the effects of Saccharomyces Boulardii capsules in the beginning of the study and two months later. Method of measurement: by interview and completing Visual Analogue Scale by patients.;Quality of life. Timepoint: In this study we checked the effects of Saccharomyces Boulardii capsules in the beginning of the study and two months later. Method of measurement: By interview and completing IMPACT III questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Bahador Mirrahimi

Shahid Beheshti University of Medical Sciences

mirrahimi@sbmu.ac.ir+98 21 2222 7020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026